Molecularly Targeted Agents in the Treatment of Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck

Hematology/Oncology Clinics of North America

Volumn 22, Issue 6, 2008, Pages 1209-1220

  Le Tourneau, Christophe ^a   Chen, Eric X ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Clinical development; EGFR; Head and neck cancer; Molecular targets; Targeted agents; VEGFR

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; IMC A 12; IRINOTECAN; K RAS PROTEIN; LAPATINIB; METHOTREXATE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PACLITAXEL; PANITUMUMAB; PEMETREXED; PLATINUM; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

BLEEDING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG FATALITY; DRUG MECHANISM; HEAD AND NECK CANCER; HUMAN; METASTASIS; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TRACHEAL HEMORRHAGE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TAXOIDS; TIME FACTORS;

EID: 55849139425     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.08.002     Document Type: Review

References (49)

1. Gibson M.K., Li Y., Murphy B., et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23 (2005) 3562-3567
2. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
3. Vermorken J.B., Trigo J., Hitt R., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25 (2007) 2171-2177
4. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002) 7350-7356
5. Rocha-Lima C.M., Soares H.P., Raez L.E., et al. EGFR targeting of solid tumors. Cancer Control 14 (2007) 295-304
6. Cohen E.E., Rosen F., Stadler W.M., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 (2003) 1980-1987
7. Wheeler RH, Jones D, Sharma P, et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca) [abstract 5531]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Orlando: 2005.
8. Cohen E.E., Kane M.A., List M.A., et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11 (2005) 8418-8424
9. Kirby A.M., A'Hern R.P., D'Ambrosio C., et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 94 (2006) 631-636
10. Stewart S, Cohen E, Licitra L, et al. A phase III randomized parallel-group study of gefitinib (Iressa) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck [abstract 3522]. In: Programs and abstracts of the American Association of Cancer Research meeting. Los Angeles: 2007.
11. Soulieres D., Senzer N.N., Vokes E.E., et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 (2004) 77-85
12. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) [abstract 5568]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Atlanta: 2006.
13. Mendelsohn J., and Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 89 (1997) 341-343
14. Baselga J., Trigo J.M., Bourhis J., et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5568-5577
15. Herbst R.S., Arquette M., Shin D.M., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5578-5587
16. Burtness B., Goldwasser M.A., Flood W., et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005) 8646-8654
17. Siu L.L., Soulieres D., Chen E.X., et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 25 (2007) 2178-2183
18. Knoedler M, Gauler TC, Matzdorff A et al. Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer [abstract 6066]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Chicago: 2008.
19. Hitt R, Irigoyen A, Nuñez J, et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC) [abstract 6012]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Chicago: 2007.
20. Bourhis J., Rivera F., Mesia R., et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24 (2006) 2866-2872
21. Vermorken J.B., and Rivera F. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359 (2008) 1116-1127
22. Buentzel J, de Vries A, Micke O. Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer [abstract 6077]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Chicago: 2007.
23. Belón J, Irigoyen A, Rodríguez I, et al. Preliminary results of a Phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck [abstract 5563]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Orlando: 2005.
24. Kim ES, Kies MS, Glisson BS, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer [abstract 6013]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Chicago: 2007.
25. Agulnik M., da Cunha Santos G., Hedley D., et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 25 (2007) 2184-2190
26. Calvo E., Malik S.N., Siu L.L., et al. Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Ann Oncol 18 (2007) 761-767
27. Le Tourneau C., Vidal L., and Siu L.L. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resist Updat 11 (2008) 99-109
28. Bissada E, Abou-Chacra Z, Weng X, et al. Prevalence of K-RAS codon 12 mutations in locally advanced head and neck squamous cell carcinoma and influence with regards to response to chemoradiation therapy [abstract 17005]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Chicago: 2008.
29. Le Tourneau C., Faivre S., and Siu L.L. Molecular targeted therapy of head and neck cancer: review and clinical development challenges. Eur J Cancer 43 (2007) 2457-2466
30. Lothaire P., de Azambuja E., Dequanter D., et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 28 (2006) 256-269
31. O-charoenrat P., Rhys-Evans P., Modjtahedi H., et al. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 18 (2000) 155-161
32. Kies MS, Gibson MK, Kim SW, et al. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): An interim analysis [abstract 6072]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Chicago: 2008.
33. Vokes EE, Cohen EE, Mauer AM, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC) [abstract 5504]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Orlando: 2005.
34. Feinstein TM, Raez LE, Rajasenan KK, et al. Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): updated results of a phase II trial [abstract 6069]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Chicago: 2008.
35. Williamson SK, Moon J, Huang CH, et al. A phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial [abstract 6044]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Chicago: 2007.
36. Elser C., Siu L.L., Winquist E., et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25 (2007) 3766-3773
37. Choong NW, Cohen EE, Kozloff MF, et al. Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) [abstract 6064]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Chicago: 2008.
38. Johnson F.M., Saigal B., Talpaz M., et al. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11 (2005) 6924-6932
39. Available at:. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=559148&ve rsion=HealthProfessional&protocolsearchid=4724336
40. Available at:. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=559632&ve rsion=HealthProfessional&protocolsearchid=4724344
41. Barnes C.J., Ohshiro K., Rayala S.K., et al. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 13 (2007) 4291-4299
42. Available at:. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=588712&ve rsion=HealthProfessional&protocolsearchid=4724347
43. Sunwoo J.B., Chen Z., Dong G., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7 (2001) 1419-1428
44. Available at:. http://www.nci.nih.gov/search/ViewClinicalTrials.aspx?cdrid=525999&v ersion=HealthProfessional&Protocolsearchid=3056999
45. Available at:. http://www.nci.nih.gov/search/ViewClinicalTrials.aspx?cdrid=409577&v ersion=HealthProfessional&Protocolsearchid=3056999
46. Ragin C.C., and Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 121 (2007) 1813-1820
47. Worden F.P., Kumar B., Lee J.S., et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 26 (2008) 138-146
48. Rampias T, Sasaki C, Burtness BA et al. Gene expression differences associated with silencing of E6 and E7 viral oncogenes in HPV16+ oropharyngeal cancer cell lines [abstract 6009]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Chicago: 2008.
49. Psyrri A, Sasaki C, Burtness BA, et al. Regulation of cytoplasmic and nuclear PTEN levels by human papillomavirus (HPV) type 16 E6 and E7 oncogenes in HPV16+ oropharyngeal cancer cell lines [abstract 6034]. In: Programs and abstracts of the American Society of Clinical Oncology meeting. Chicago: 2008.